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Abstract
Immunosuppression is commonly used for prevention of graft rejection 
in solid organ transplantation (SOT) and prevention of graft versus host 
disease in hematopoietic allogeneic stem cell transplant (ASCT). In ASCT, 
immunosuppression is used to control GVHD and can be tapered off within 
6–12 months after transplantation. SOT recipients require lifelong immunosup-
pression to prevent graft rejection, making them susceptible to serious viral 
infections including EBV PTLD. EBV PTLD occurs within the first 6 months 
following ASCT prior to effective reconstitution of cytotoxic T lymphocytes 
(CTL). Our understanding on EBV-related PTLD is mostly extrapolated from 
SOT-associated PTLD. Features of conditioning and use of serotherapy remain 
important in development of EBV PTLD. Other viral infections that occur 
early post-transplant include CMV, HHV6, BK, and adenovirus, and usually 
correspond to degree of immunosuppression post-transplant. These infections 
are associated with significant morbidity and mortality. However, the current 
literature lacks information on outcomes of viral infections related to immu-
nosuppression. Alternative donor ASCT are now more common, and patients 
are more susceptible to multiple viral infectious complications at the peak of 
immunosuppression and require monitoring for viral infections in these immu-
nosuppressed patients.
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1. Immunosuppression
Immunosuppression is commonly used for prevention of graft rejection in 
solid organ transplantation (SOT) and prevention of graft versus host disease in 
hematopoietic allogeneic stem cell transplant (ASCT). In solid organ transplanta-
tion (SOT), the donor grafts are recognized as non-self by the recipient’s immune 
system. The recipient immune system can cause T-cell-mediated rejection and 
antibody-mediated rejection at any time. Immunosuppression is critical to control 
the recipient immune system and protect donor organs from rejection. Therefore, 
immunosuppression is generally necessary as long as the patient retains a viable 
donor graft.
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In allogenic hematopoietic cell transplantation, donor-derived hematopoietic 
stem cells and lymphocytes replace the hematopoietic system as well as the immune 
system of the recipient. While donor T-cells provide anti-pathogen and anti-tumor 
activity to the recipient, donor-derived alloreactive T-cells are responsible for graft 
versus host disease (GVHD). Immunosuppression is used to control acute and 
chronic GVHD. However, alloreactive T-cells are eventually eliminated in most 
patients, and immunosuppression can be tapered off within 6–12 months after 
transplantation in ASCT. Solid organ transplant recipients, on the other hand, 
require lifelong immunosuppression to prevent graft rejection, making them 
susceptible to EBV virus mediated post-transplant lymphoproliferative disorder 
(PTLD). In ASCT, some patients who develop chronic GVHD also need prolonged 
immunosuppression requiring monitoring and treatment of complications related 
to serious viral infections.
In cord transplant recipients and, more recently, in haploidentical transplant 
and mismatched transplant patients, with the effect of antithymocyte globulin 
(ATG) and other T-cell depleting regimens, patients are even more susceptible than 
usual to either single or multiple viral infectious complications at the peak of immu-
nosuppression. Use of TNF receptor blockers including etanercept and infliximab 
for GVHD or Crohn disease, the use of other interleukin inhibitors for skin GVHD, 
and other autoimmune disorders are additional examples of ongoing immunosup-
pression that would require monitoring for viral infections and complications in 
these immunosuppressed patients.
The most common immunosuppression to prevent GVHD is the use of 
calcineurin inhibitors tacrolimus and cyclosporine. Calcineurin is an essential 
enzyme in the activation of T-cells. Both tacrolimus and cyclosporine have similar 
mechanisms of action and efficacy. In the post-transplant period, monitoring of 
tacrolimus and cyclosporine serum levels is performed as a surrogate for depth 
and degree of immunosuppression. In the early post-transplant period, a higher 
serum levels are essential until alloreactive T-cells are eliminated, at which point 
lower serum levels can still prevent GVHD. Other immunosuppressants used 
post-transplant include mycophenolate mofetil and mycophenolate sodium, 
which exhibit a cytostatic effect on T- and B-lymphocytes. Cyclophosphamide 
is now routinely given in the post haploidentical or mismatched transplant 
setting to reduce the incidence of GVHD by selective removal of alloreactive 
donor T-cells.
In the post-treatment phase beyond 100 days, the presence of chronic GVHD 
is the main determinant of infection. Patients who developed acute GVHD expe-
rience approximately 60% more infections than patients who do not develop 
acute GVHD. Furthermore, patients who experience chronic GVHD have their 
immunosuppression increased or restarted, therefore increasing the risk of 
infection.
2. EBV infection
EBV PTLD develops in approximately 1% of patients post ASCT. It is highly 
related to EBV reactivation. Risk factors that associate with high incidence of 
EBV-related PTLD include older age at transplant, T-cell depletion-containing 
conditioning regimens, antithymocyte globulin (ATG) use, and grafts derived from 
unrelated or HLA-mismatched donors [1–5]. PTLD in ASCT patients occurs in 
the younger age group, with shorter duration of onset as compared to (SOT) solid 
organ transplantation.
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EBV PTLD occurs more commonly in pediatric patients than in adults 
because more pediatric patients are EBV naïve. PTLD can occur during the post-
transplant period after both myeloablative and non-myeloablative ASCT. The 
degree and duration of immunosuppression plays a major role in the develop-
ment of PTLD. Cytotoxic T lymphocytes (CTLs) provide a defense mechanism 
against EBV-infected B cells in immunocompetent individuals. However, T cell 
function is impaired post allogeneic transplant which leads to the development 
of PTLD. In vivo T cell depletion (TCD) with antithymocyte globulin (ATG) 
or alemtuzumab (AL) is commonly used in ASCT. As reduced intensity condi-
tioning (RIC) and matched unrelated donor (MUD) transplants are now being 
performed more frequently, ATG and AL have become integral components 
of preparative regimens to facilitate engraftment and reduce the incidence 
and severity of GVHD. Delayed T cell reconstitution following T cell depletion 
accounts for infectious complications including PTLD, which is associated with 
increased mortality [3, 4].
EBV PTLD can occur later in the most severely immunocompromised 
patients with additional risk factors such as donor and recipient mismatch, 
graft manipulation with T cell depletion as well as the degree and duration of 
immunosuppression. Prevention of PTLD involves limiting the duration and 
degree of immunosuppression, while still maintaining the adequacy of the 
donor graft. Achieving a balance of reduction in immunosuppression and pre-
venting graft rejection or graft versus host disease can be challenging. Antiviral 
prophylaxis may also play a role in preventing PTLD. The use of antiviral 
agents such as acyclovir, valganciclovir, and ganciclovir are common for HSV, 
CMV, and EBV prophylaxis, though data is very limited for prevention of EBV 
PTLD [2–5].
EBV monitoring of high-risk patient facilitates preemptive rituximab or 
tapering of immunosuppression upon viremia proceeding PTLD. Successful 
clearance of EBV and prevention of PTLD has been reported with B-cell deple-
tion by rituximab [6–8]. On the other hand, antiviral agents, such as acyclovir, 
ganciclovir, and valganciclovir are not widely used for prevention, due to 
limited data. [2–5]. The use of “Off-the-shelf,” third-party EBV-specific CTLs 
is a new promising approach to treat refractory PTLD to rituximab or immu-
nosuppression tapering [3]. Treatment algorithm for EBV PTLD is as shown in 
Tables 1 and 2.
Table 1. 
Treatment algorithm for EBV positive PTLD.
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3. Other viral infections
Other viral infections that occur early post-transplant include CMV, HHV6, 
BK, and adenovirus, and usually correspond to degree of immunosuppres-
sion post-transplant [4, 9]. However, the current literature lacks information 
on outcomes of viral infections as well as the influence of graft sources, such 
as comparison of outcomes between umbilical cord blood transplant (UCBT) 
and haploidentical transplant (haplo) with post-transplant cyclophosphamide 
(PTCy) [10]. These infections usually occur within in early post-transplant 
period prior to effective immune reconstitution [1, 11, 12]. Despite advances 
in antiviral therapy, severe infections still remain a major cause of death after 
alternative donor ASCT [5, 9, 13].
In a prospective analysis of immune reconstitution in double UCBT recipients 
and matched unrelated donor (MUD) recipients, CD3 recovery was significantly 
delayed in the double UCBT group compared with MUD group for as long as 
6 months after ASCT [5, 9, 13]. These unique properties of UCBT may contribute 
to a high risk of infection reported in some studies. Novel strategies are now being 
developed to combat viral infections including the virus-specific or trivirus-specific 
(adenovirus, Epstein-Barr virus, and cytomegalovirus) CTLs [14–16]. Early diag-
nostic information regarding viral infections is critically important in the current 
era of emerging new therapies for viral infections.
4. CMV infection
CMV infection occurs in 50–80% of the population and CMV virus is main-
tained in a latent reservoir in mononuclear leukocytes. Containment of CMV in its 
latent state affects a large proportion of host immune repertoire. In young adults, 
1–2% of CD4 and CD8 T cells are CMV-reactive, which rise to up to 30–40% in the 
elderly. For the majority of CMV-infected individuals, asymptomatic reactivation 
is effectively countered by innate and adaptive immunity. In the immunocompro-
mised ASCT patients, unconstrained viral replication and dissemination can lead 
to CMV disease, and increased mortality due to end-organ damage. The efficacy of 
conventional antiviral therapies including ganciclovir and foscarnet is limited in the 
setting CMV disease with end-organ involvement [17].
CMV-seropositive patients will experience CMV dissemination after ASCT, 
particularly in the context of transplant using T cell-depleted or matched unrelated 
Table 2. 
Treatment algorithm for EBV negative PTLD.
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donor (MUD) grafts. In CMV-seronegative patients, CMV infection is prevented 
through selection of CMV-seronegative grafts, but 20–40% of CMV-seronegative 
patients who receive CMV-seropositive grafts develop primary CMV infection. 
Untreated, 50% of ASCT patients with CMV reactivation will develop CMV 
disease. The current clinical practice uses close surveillance monitoring of CMV 
DNA burden by quantitative PCR (qPCR). Preemptive antiviral pharmacotherapy 
and prophylactic therapy strategies are used to reduce the incidence of CMV disease 
after ASCT. Novel antiviral pharmacotherapies including maribavir, letermovir, 
and brincidofovir are under clinical trial development but have not yet clearly 
demonstrated superiority or lesser toxicity compared to conventional antiviral 
agents [17].
5. Adenovirus viral infections
Adenovirus (AdV) infections are much more common in pediatric patients 
(20–26%) than in adults (9%) undergoing ASCT. In the severely immunocompro-
mised patients, Adv can cause severe respiratory viral disease, hepatitis, and colitis. 
Other complications include hemorrhagic cystitis and adenoviral keratoconjuncti-
vitis. AdV infection can cause subclinical viremia, viremia with disease symptoms, 
and disseminated disease. The incidence of disseminated disease is 1–7% with 
mortality of 8–26%. Rapidly increasing or persistent viremia is associated with the 
occurrence of severe adenoviral disease both in children and in adults. Monitoring 
of the viral load by blood AdV qPCR is far superior with high sensitivity. A study 
in adult ASCT recipients has reported an infection rate of 2.5% with pneumonia 
occurring in 24% of cases as the most common cause of death. Viral gastrointestinal 
shedding prior to transplant is found to be associated with increased risk of viremia 
after ASCT [18]. Treatment of adenoviral infections include Cidofovir, brincidofo-
vir (compassionate use in children) and use of IVIG as well as taper of immunosup-
pression. More recent studies have used nucleofection to introduce DNA plasmids 
encoding multiple immunogenic antigens from CMV, EBV, and adenovirus into 
APCs to control lethal adenoviral infections.
6. HHV6 infection
Human herpesvirus 6 (HHV6), a member of β-herpesvirus subfamily, estab-
lishes primary infection as exanthem subitum in the normal pediatric population. 
With time, it establishes latency in CD34+ cells, monocytes, and macrophages, 
similar to cytomegalovirus (CMV). Over the last decade, HHV6 has been increas-
ingly recognized as an opportunistic and potentially life-threatening pathogen 
after ASCT [1–5, 9, 13–16, 18]. Following ASCT, HHV6 infections are caused by 
reactivation of the virus from latency. HHV6 reactivation is detected in the blood 
of 40–60% of patients after ASCT, most often by use of qPCR for viral-specific 
sequences.
HHV6 viremia has been reported in association with varying organ dysfunction 
and clinical syndromes including delayed/impaired platelet recovery, myelosup-
pression, encephalitis, fever, rash, hepatitis, pneumonitis, gastroduodenitis, CMV 
reactivation, and GVHD.
Treatment indications are uncertain in patients with HHV6 viremia following 
ASCT. HHV6 encephalitis is potentially fatal and is a common indication for treat-
ment. Only one trial evaluated preemptive treatment of HHV6 based on a positive 
qPCR test. The development of reliable clinical guidelines for the management of 
Immunosupression
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HHV6 viremia in ASCT recipients has historically been limited by the lack of speci-
ficity of viremia testing and by the lack of specific HHV6 clinical syndromes. It is 
also confounded by the occurrence of asymptomatic viremia, which often resolves 
without intervention. Treatment algorithm for HHV6 is as shown in Table 3.
7. BK virus infection
The BK virus infection is associated with hemorrhagic cystitis in ASCT recipi-
ents. Treatment interventions are mainly focused on supportive measures includ-
ing hyperhydration, continuous bladder irrigation, and topical agents to alter the 
bladder mucosal lining. In the recent years, BK virus PCR in the urine and plasma 
has helped with early detection of BK virus infection and BK hemorrhagic cystitis 
(BK-HC) as higher urine and plasma viral loads are associated with disease manifes-
tation including BK-HC [19, 20].
Other treatments of BK-HC aim at repair and regeneration of the urothelial 
mucosa through hyperbaric oxygen therapy or by topical application of fibrin. Use of 
hyperbaric oxygen has limited availability and also the risk of barotrauma and claus-
trophobia [19]. Finally, topical fibrin glue applications to the damaged bladder mucosa 
to achieve hemostasis through cystoscopy have been reported in single-center retro-
spective series of 35 patients with complete response rate of 83%. Several compounds 
to reduce bleeding have been used in small studies which include FXIII concentrate, 
intravesical sodium hyaluronate, estrogens or choreito extract granules with response 
rates between 50 and 100% [19]. Brincidofovir, a lipid conjugate of cidofovir has a 
potent and long-lasting inhibitory effect on BK virus replication in vitro studies but 
no data are available on the clinical use in BK nephropathy after ASCT. Brincidofovir 
may have the future indication for symptomatic BK-HC considering the absence of 
alternative antivirals with a better safety and tolerability profile [19, 20].
The reduction of immunosuppression has been used successfully in kidney 
transplant patients to prevent and/or treat BK nephropathy, but there is no evi-
dence that it has a favorable risk/benefit ratio in ASCT patients due to the risk of 
worsening donor alloreactivity and severity of GVHD. Unlike for BK nephropathy, 
there is no documented benefit in using intravenous immunoglobulin (IVIG) 
for BK-HC. Extrapolating from use in BK virus nephropathy in renal transplant 
patients, cidofovir and leflunomide are only currently available agents for the 
treatment of BK-HC and fluoroquinolone antibiotics are considered as possible 
prophylactic agents.
Treatment algorithm for BK is as shown Table 4.
Table 3. 
Treatment of HHV6 infection.
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8. HSV/VZV infection: herpesviruses
The herpesvirus group currently consists of eight members, six of which 
have been implicated as important pathogens in ASCT recipients. During recent 
years, antiviral agents are used both for prevention and therapy in ASCT patients. 
Currently available anti-herpesvirus drugs are acyclovir and its prodrug valacyclo-
vir, penciclovir and its prodrug famciclovir, ganciclovir with the prodrug valgan-
ciclovir, cidofovir, and foscarnet. All of the available drugs, except foscarnet, are 
nucleoside analogues and require phosphorylation by viral or cellular enzymes to 
become activated (Tables 5 and 6).
Table 4. 
Treatment of BK infection /BK cystitis.
Table 5. 
Treatment of HSV infection.
Table 6. 
Treatment of VZV infection.
Immunosupression
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9. Herpes simplex virus (HSV)
The first controlled studies of prophylaxis and therapy of HSV in ASCT patients 
were performed more than 20 years ago, showing that effective antiviral agents can 
make an important impact on morbidity and mortality. The results from these early 
trials showed that acyclovir prophylaxis is indicated in all HSV-seropositive ASCT 
recipients and in some autologous patients with high risk for mucositis [21]. The 
duration of antiviral prophylaxis should be adjusted for each individual but should 
be continued throughout the aplastic phase. A longer duration of prophylaxis 
should be considered in patients with GVHD or a history of frequent reactiva-
tions before transplantation [21]. It is important to realize that HSV reactivations 
frequently occur quickly after prophylaxis is stopped and might require therapy 
long-term prophylaxis [22].
Valacyclovir, the prodrug of acyclovir, is also used as prophylaxis but no 
controlled studies have been performed in transplant patients. Valacyclovir gives 
similar acyclovir serum levels to IV acyclovir in neutropenic patients. Established 
HSV disease can be treated either orally or intravenously. The most commonly used 
drug is acyclovir, which should be given intravenously in patients with disseminated 
HSV or suspected central nervous system (CNS) disease therapy [22].
The most frequently used agents for HSV prophylaxis and therapy all require 
the viral enzyme thymidine kinase for activation. Virus resistance occurs with the 
development of mutant lacking this enzyme. Although acyclovir has been in use 
for almost 20 years, there has been only a moderate increase in acyclovir-resistant 
strains of HSV. Recently, acyclovir-resistant HSV have become more common, 
in unrelated and HLA-mismatched ASCT recipients and in patients who develop 
GVHD. The recommended drug for acyclovir-resistant HSV has been foscarnet. 
Currently, the only available antiviral drug available for treatment of double 
resistant HSV is cidofovir. However, although sensitive in vitro, the clinical response 
in high-risk ASCT patients treated with cidofovir has been variable [22].
10. Varicella-Zoster virus (VZV)
VZV infection is a very severe complication in ASCT patients. The risk is highest 
in children due to the epidemiologic pattern of infection. The live Varicella vaccine 
has been shown to be safe in children with acute leukemia but no controlled trial 
in ASCT recipients has been published and its use is not recommended earlier than 
24 months after transplantation. Varicella-zoster immune globulin is the recom-
mended prophylactic measure in seronegative ASCT recipients after an exposure to 
varicella has occurred if it can be given within 4 days of exposure [21, 22]. Another 
option is antiviral chemoprophylaxis with acyclovir or valacyclovir but there is no 
published data regarding the efficacy of this strategy.
11. Prevention of reactivated infection of VZV
The risk of herpes zoster is highest between 3 and 6 months after transplanta-
tion. Thus, the duration of antiviral prophylaxis must be long enough to prevent 
reactivated VZV disease. Two randomized, controlled studies have been performed 
comparing 6 months of prophylactic acyclovir with place. In addition, a non-
controlled study of acyclovir or ganciclovir prophylaxis was recently published. 
All three studies showed that acyclovir was effective in reducing the risk for herpes 
zoster during the 6 months of therapy but at 12 months after transplantation there 
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was no longer any difference. An unpublished study by Bowden and colleagues 
from the Seattle group indicated that the rebound in VZV disease does not occur if 
the prophylaxis is prolonged to 12 months [23]. Valacyclovir has not been studied 
for VZV prophylaxis, but the rate of VZV disease was reduced in a study when vala-
cyclovir was compared to acyclovir as CMV prophylaxis. Some centers, however, do 
use valacyclovir as long-term prophylaxis against VZV [21, 22].
12. Treatment of VZV disease
The recommended therapy for a primary varicella or disseminated herpes 
zoster is intravenous acyclovir 10 mg/kg (or 500 mg/m2) three times daily. For 
localized dermatomal herpes zoster, oral acyclovir 800 mg given five times daily 
was compared with IV acyclovir in a small randomized study in ASCT patients 
and the outcome was comparable. Famciclovir 500 mg given three times daily was 
compared with acyclovir 800 mg five times daily in ASCT, solid organ transplant 
and oncology patients, and the results indicated similar efficacy. No controlled 
study has been performed with valacyclovir given for treatment of a herpes zoster 
in ASCT patients. VZV resistance to acyclovir is rare but has been reported after 
ASCT [22, 23].
Treatment algorithm for HSV/VZV is as shown in Tables 5 and 6.
13. Other upper respiratory infections
The conditioning regimen has an impact on the incidence of these infections. 
Even though the patients with myeloablative and non-myeloablative condition-
ing have similar incidences for respiratory viral infections, LRI are significantly 
increased during the early post myeloablative ASCT period compared to non-
myeloablative ASCT [14, 15].
14. Treatment of respiratory viral infections post ASCT
Lower overall survival seen with respiratory virus infection is due to bacterial 
co-infection causing increased mortality in high-risk patients with lymphopenia, 
CMV DNAemia at the time of viral LRI and need for oxygen support. Over the 
past years, more respiratory infections in ASCT recipients have been reported due 
to the use of new multiplex polymerase chain reaction (PCR) tests with higher 
sensitivity, specificity compared to conventional viral culture and antibody assays. 
Early diagnosis and treatment are important to improve outcomes of patients with 
upper respiratory viral infections (URI) s and lower respiratory viral infections 
(LRI)s [14, 15].
15.  CMV-specific T cell lines and multi virus-specific T cell lines 
(multi-VST)
Immunotherapeutic strategies to hasten T cell recovery after ASCT remain 
an option as an adjunct to drug treatments. CMV-seropositive patients who are 
recipients of T cell-depleted CMV-seronegative donor or cord blood grafts are at 
highest risk from CMV-associated morbidity and mortality. Severe GVHD and 
drug-induced T cell dysfunction are also risk factors for CMV-related morbidity. 
Immunosupression
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Recovery of CMV-specific CD4 responses is critical to effective antiviral responses, 
and restoration of both antigen-specific CD4 and CD8 T cell populations to control 
CMV is critical in this scenario [14–16].
An alternative to CMV-specific T cell clones is the use of CMV-specific T cell 
lines. In a clinical study, a single infusion of CMV-specific CD4 T cells showed 
plasma CMV clearance in 63% of patients. The HLA-A2–restricted pp65 peptide 
NLVPMVATV (NLV) is also being used but a major disadvantage of the HLA-A2–
restricted NLV peptide approach is the restriction of benefit to HLA-A2+ patients 
only [10, 16, 17].
Multi-VST lines represent an interesting option to target multiple viral infec-
tions using adoptive cell therapy. Such lines can be manufactured either with APC 
systems using overlapping peptide pools from multiple viruses, or with other 
gene transfer approaches by the use of an adenoviral vector encoding the CMV-
associated pp65 antigen to transduce APCs (MoDCs and EBV-transformed lympho-
blastoid cell lines [LCLs]) before coculture with PBMCs or naive cord blood. This 
method delivers both MHC class I-dependent processing and expansion of CMV-
reactive CD8 T cells, and MHC class II-dependent processing and presentation of 
adenovirus/EBV/CMV-associated peptides to drive expansion of virus-specific CD4 
T cells. The adenoviral transfer vector promotes anti-adenoviral T cell specificity 
(bispecific CTLs), and if EBV-transformed B cells are used in lieu of MoDCs, then 
additional EBV-specificity is generated (trispecific CTLs) [10, 16, 17].
Trispecific CTLs administered prophylactically has demonstrated CMV-specific 
reactivity in 70% of patients with no increase in the incidence of GVHD. CMV- and 
EBV-specific T cell numbers rise in the absence of viral reactivation, but adenoviral-
CTL expansion is only observed in the context of adenoviral infection. More recent 
studies have used nucleofection to introduce DNA plasmids encoding multiple 
immunogenic antigens from CMV, EBV, and adenovirus into APCs, or have used 
viral antigen–derived 15-mer peptide libraries (pepmix) with APCs to deliver a 
product with a broader CMV-reactive T cell repertoire [10, 16, 17].
16. Conclusion
Increased numbers of both systemic and upper respiratory tract viral infections 
occur post-transplant due to ineffective immune reconstitution. Early diagnosis 
and treatment are critically important to reduce morbidity and mortality associ-
ated with these infections. Viral infections cause morbidity and mortality in these 
immunosuppressed patients due to inability of the host immune system to limit 
viral replication and dissemination, and loss of T cell function is central to this 
effect. Immunotherapeutic strategies to accelerate reconstitution of virus-specific 
immunity and to hasten T cell recovery after transplants remain a compelling alter-
native to drug treatments. CMV- and EBV-directed virus-specific T cells (VSTs) are 
being used in the settings of profound immunosuppressed SOT and ASCT patients. 
Emerging evidence supports the use of VSTs for treatment of broader range of viral 
targets, including varicella-zoster virus, adenovirus, and BK virus [10, 14–17].
Abbreviation
EBV Epstein Barr Virus
PTLD post-transplant Lymphoproliferative disorder
IST immunosuppression
HHV6 human Herpes simplex virus 6
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